NKTR Nektar Therapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
11:27
May 27
May 27
Author discloses an active long position in NKTR in the context of APGE 16-week Part B data release, suggesting NKTR benefits from the read-through (pink eye indication viewed positively).
MED
11:27
May 27
May 27
Author states a current long position in NKTR, with cryptic references to a clinical data readout (implied biotech catalyst), though reasoning is not explicitly articulated.
MED
11:27
May 27
May 27
Author expresses bullish conviction on NKTR with a long position while noting APGE's upcoming data catalyst, suggesting a positive outlook for NKTR.
20:04
May 26
May 26
The tweet notes upcoming data for APGE and mentions NKTR and CRVS without expressing a directional view or trade idea.
LOW
19:24
May 24
May 24
Buy NKTR on litigation catalyst and differentiated durability/quarterly dosing of rezpeg; cancer risk concerns dismissed with no signal over >1000 patients.
MED
20:01
May 19
May 19
The author reflects on the value of contrarian perspectives and open-mindedness in trading, mentioning NKTR as a stock where they have disagreed with others, but expresses no forward-looking directional view.
HIGH
18:19
May 19
May 19
Author adds to ABVX and NKTR positions ahead of key data, expressing bullish conviction on ABVX's high probability of meeting endpoints while holding other biotech names for later review.
HIGH
19:34
May 14
May 14
NKTR is undervalued based on its AtD catalyst and should be worth at least double the current price, making it a long opportunity.
HIGH
17:10
May 14
May 14
Buy NKTR as enterprise value undervalues peak sales potential of drug AtD, with insider accumulation indicating conviction.
HIGH
14:47
May 14
May 14
The author predicts NKTR will rise 20% on a potential ABVX takeover, expressing a bullish speculative view on NKTR.
HIGH
17:59
May 11
May 11
Buy NKTR as price trades $15 below offering price and enterprise value is below peak sales potential of its drug AtD, signaling undervaluation.
HIGH
12:56
May 08
May 08
Buy NKTR for its bold Phase 3 in biologic-refractory atopic dermatitis; if successful, it could capture a unique label and >$5B peak sales, making the undervalued stock a prime M&A target.
HIGH
12:04
May 08
May 08
Buy NKTR on its phase 3 trial targeting exclusive label claim for biologic-refractory atopic dermatitis, a significant competitive catalyst if successful.
HIGH
17:44
May 07
May 07
Long NKTR as part of a biotech portfolio with high conviction based on proprietary research.
HIGH
08:54
Apr 30
Apr 30
The author sold all ANL and now holds only NKTR, ABVX, and COGT, signaling a concentrated bullish bet on these biotech names ahead of summer catalysts.
02:04
Apr 30
Apr 30
Tweet mentions $NKTR with a link; no directional view, reason, or catalyst stated.
LOW
00:01
Apr 29
Apr 29
Bearish view on NKTR: its sparse dosing without YTE is dismissed as worthless by the speaker, undermining its drug technology's competitive value.
HIGH
19:33
Apr 27
Apr 27
Buy NKTR on weakness as AtD asset alone justifies triple-digit valuation, making current price undervalued.
HIGH
15:27
Apr 26
Apr 26
Adam May pitches Abivax as a high-upside biotech play with a 10x+ potential, citing a favorable data-driven risk/reward similar to his earlier successful NKTR call.
HIGH
10:59
Apr 24
Apr 24
Buy NKTR as offering closes, Q4 catalyst and litigation news approach, and Phase 3 cash concerns are resolved, with a year-end price target of $160.
MED
20:03
Apr 20
Apr 20
Buy NKTR as the stock tends to rally significantly after completing an equity offering, with current low volume indicating sidelined real buyers are ready to step in.
MED
14:08
Apr 20
Apr 20
Accumulate Nektar Therapeutics as the market is currently underpricing the significance of recent clinical data, presenting a setup similar to historical biotech winners.
HIGH
14:00
Apr 20
Apr 20
Go long expecting an intraday post-data rally similar to historical precedent, anticipating an upcoming equity offering at a higher price level.
HIGH
13:16
Apr 20
Apr 20
Buy NKTR as Eli Lilly's surprisingly high buyout valuation of Kelonia suggests their upcoming legal settlement with Nektar Therapeutics will also be significantly larger than market expectations.
MED
12:18
Apr 20
Apr 20
Buy NKTR on premarket weakness following news, anticipating an intraday reversal and multi-week rally similar to the price action seen after the February AtD maintenance data release.
HIGH
12:05
Apr 20
Apr 20
Go long NKTR as its first-line treatment for alopecia areata and upcoming dual indication launch position it to disrupt a massive dermatology market currently dominated by JAK inhibitors.
HIGH
11:32
Apr 20
Apr 20
Buy NKTR because new high-dose clinical data shows a significant reduction (27.6%) in the SALT biomarker below 20, a positive efficacy signal that could drive the stock higher.
MED
11:32
Apr 20
Apr 20
The tweet expresses strong positive sentiment about Nektar Therapeutics, suggesting the company has released favorable news or data.
14:06
Apr 17
Apr 17
Buy NKTR as it is a genuinely innovative biotech company that is currently being unfairly punished by a market favoring generic targets.
MED
About NKTR Analyst Coverage
Buzzberg tracks NKTR (Nektar Therapeutics) across 2 sources. 24 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (63%). 38 total trade ideas tracked.